Every S-3 that Cormedix (CRMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow CRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRMD filings page.
CorMedix, Inc. (CRMD) filed an S-3ASR prospectus registering up to 6,323,833 shares of common stock to be sold by existing selling securityholders rather than by the company. The selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with Fund IV accounting for up to 4,853,542 shares (consisting of 2,551,042 merger-issued shares and up to 2,302,500 milestone shares) and Fund III accounting for up to 1,470,291 shares (consisting of 772,791 merger-issued shares and up to 697,500 milestone shares). Milestone shares are issuable under a contingent purchase agreement and will be valued using the five-day volume weighted average price on NASDAQ preceding each milestone date through June 30, 2029. The prospectus states the company will receive no proceeds from these sales and lists $140,000 of legal fees and expenses. The company's common stock trades on the Nasdaq Global Market under the symbol CRMD.
CorMedix, Inc. (CRMD) filed a shelf registration on Form S-3ASR to allow selling securityholders to offer up to 6,323,833 shares of common stock. The company will not receive proceeds from these sales. Principal selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with detailed allocations showing 2,551,042 and 772,791 shares issued under the Merger Agreement, plus potential 2,302,500 and 697,500 milestone shares issuable under a contingent purchase agreement (CPA) through June 30, 2029. Shares for milestones will be valued using the five-day VWAP before each milestone date. The prospectus references risk factors and incorporates the company Form 10-K for fiscal 2024 filed March 25, 2025. A listed legal fees line item shows $140,000.
CorMedix Inc. (CRMD) has a shelf prospectus for resale of up to 6,323,833 shares of common stock by selling securityholders; the company will not receive proceeds from those sales. The shares include amounts issued under a Merger Agreement and potential milestone shares issuable under a Collaboration and Purchase Agreement (CPA) through June 30, 2029, with milestone share valuation tied to a five-day VWAP on the Nasdaq prior to each milestone. Named selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with specified allocations of Merger and potential milestone shares. The Nasdaq Global Market ticker is CRMD. The prospectus refers investors to the Risk Factors section and incorporated reports for further details.